In this innovative and challenging book, William Pardridge, a world leader in the study of the blood-brain barrier and its clinical implications, argues that brain drug development has been restricted by the failure of adequate brain drug targeting. This is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system.
"synopsis" may belong to another edition of this title.
Brain drug development has been restricted by the failure of adequate brain drug targeting, an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. This challenging book reviews the field of neurotherapeutics from the point of view of drug targeting, surveying the scientific and clinical basis of drug delivery across biological membranes. It will encourage a wide range of clinicians and neuroscientist s to reexamine the development and use of drugs in treating disorders of the central nervous system.
"Just as the author does an excellent job arguing for the need for more work in this area, he also goes in depth describing all the inherent pitfalls as well as possible solution necessary to develop large-molecule pharmaceuticals for brain disease." The Annals of Pharmacotherapy April 2002
"...a book that will become a standard on drug targeting to the brain...a must for everybody who works in the field of brain drug delivery in academia as well as in the pharmaceutical industry." Journal of Clinical Pathology
"This is an excellent book, to be expected from a major researcher in the field. The lucid text is illuminated by an eclectic mix of diagrams and plates that will have a broad appeal to a wide audience within the biomedical, pharmaceutical and imaging sciences." British Journal of Neurosurgery
"About this title" may belong to another edition of this title.
Seller: Grand Eagle Retail, Bensenville, IL, U.S.A.
Paperback. Condition: new. Paperback. The thesis of this innovative and challenging book, first published in 2001, is that brain drug development has been restricted by the failure of adequate brain drug targeting, and that this is an increasingly urgent problem as developments in genomics lead to new generations of therapeutic macromolecules. The author, a world leader in the study of the blood-brain barrier and its clinical implications, reviews the field of neurotherapeutics from the point of view of drug targeting. He surveys the scientific and clinical basis of drug delivery across biological membranes, including topics such as genetically engineered trojan horses for drug targeting, antisense neurotherapeutics, and gene therapy of brain disorders. At a time when there are few significant new drug treatments in prospect for common neurological diseases, this authoritative review will encourage a wide range of clinicians and neuroscientists to reexamine the development and use of drugs in treating disorders of the central nervous system. This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting, surveying the scientific and clinical basis of drug delivery across biological membranes. It will encourage a wide range of clinicians and neuroscientists to reexamine the use of drugs in treating disorders of the central nervous system. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Seller Inventory # 9780521154468
Seller: California Books, Miami, FL, U.S.A.
Condition: New. Seller Inventory # I-9780521154468
Seller: Revaluation Books, Exeter, United Kingdom
Paperback. Condition: Brand New. reissue edition. 353 pages. 9.75x7.00x0.75 inches. In Stock. This item is printed on demand. Seller Inventory # __0521154464
Quantity: 1 available
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Condition: New. In. Seller Inventory # ria9780521154468_new
Quantity: Over 20 available
Seller: Chiron Media, Wallingford, United Kingdom
PF. Condition: New. Seller Inventory # 6666-IUK-9780521154468
Quantity: 10 available
Seller: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Ireland
Condition: New. This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting. Num Pages: 376 pages, black & white illustrations. BIC Classification: MJN; MMGW. Category: (P) Professional & Vocational. Dimension: 244 x 170 x 20. Weight in Grams: 600. . 2010. Reissue. paperback. . . . . Seller Inventory # V9780521154468
Quantity: Over 20 available
Seller: Books Puddle, New York, NY, U.S.A.
Condition: New. pp. 376. Seller Inventory # 26615854
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. Print on Demand pp. 376 67:B&W 6.69 x 9.61 in or 244 x 170 mm (Pinched Crown) Perfect Bound on White w/Gloss Lam. Seller Inventory # 8313457
Quantity: 4 available
Seller: Kennys Bookstore, Olney, MD, U.S.A.
Condition: New. This challenging 2001 book reviews modern neurotherapeutics from the point of view of drug targeting. Num Pages: 376 pages, black & white illustrations. BIC Classification: MJN; MMGW. Category: (P) Professional & Vocational. Dimension: 244 x 170 x 20. Weight in Grams: 600. . 2010. Reissue. paperback. . . . . Books ship from the US and Ireland. Seller Inventory # V9780521154468
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New. PRINT ON DEMAND pp. 376. Seller Inventory # 18615844
Quantity: 4 available